TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06697301: Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

Sponsor: Eikon Therapeutics · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 740 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$4,340,028

Rescue Site Savings

+$2,874,564

Unlock Full NCT06697301 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06697301 Rescue Dossier →